T-Therapeutics closed an oversubscribed $133 million Series B to advance two TCR-CD3 bispecific programs—one in oncology and one in autoimmune disease—toward clinical proof-of-concept. The funding supports clinical development through early-stage milestones using the company’s OpTiMus platform. The round was co-led by new investors Advent Life Sciences and the British Business Bank, alongside participation from strategic and institutional investors including Johnson & Johnson Innovation, Samsara BioCapital, and Eli Lilly. Existing major shareholders also participated, signaling broad backing for both solid-tumor targeting and precision immunomodulation. The company’s approach centers on supplying a large repertoire of fully human TCRs to access intracellular targets it describes as previously undruggable. Both lead programs aim to move beyond conventional therapies by improving selectivity and resetting immune function in chronic inflammation settings. For the broader cell-therapy and bispecific landscape, the financing underscores investor confidence in TCR-based cell engagers as a differentiating modality beyond standard antibody binding formats.